NME4 promotes de novo lipogenesis potentially through the direct binding and activation of key enzymes involved in CoA metabolism, ultimately leading to lipogenesis and steatosis in NAFLD. Here, NME4 is linked to metabolic dysfunction-associated steatotic liver disease.